Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • 5-HT Receptor
    (4)
  • AMPK
    (1)
  • Antiviral
    (1)
  • Apoptosis
    (2)
  • Autophagy
    (1)
  • BCL
    (1)
  • DUB
    (2)
  • IL Receptor
    (2)
  • Neuropeptide Y Receptor
    (2)
  • Others
    (59)
Filter
Search Result
Results for "

dose-dependently

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    106
    TargetMol | Activity
  • Peptide Products
    14
    TargetMol | inventory
  • Natural Products
    12
    TargetMol | natural
  • Recombinant Protein
    1
    TargetMol | composition
ABT-963
T26531266320-83-6In house
ABT-963 is a potent and selective inhibitor of disubstituted pyridazinone cyclooxygenase-2 (LOX2) that dose-dependently reduces injury perception in a carrageenan model of nociceptive sensitization.ABT-963 is used in the study of arthritis.
  • $293 TargetMol
In Stock
Size
QTY
Ezurpimtrostat hydrochloride
T628821914148-73-4In house
Ezurpimtrostat hydrochloride (GNS561 hydrochloride) is an orally available palmitoyl protein thioesterase-1 inhibitor with antifibrotic, antiviral, and anticancer effects that blocks cancer cell proliferation by interacting with palmitoyl protein thioesterase to inhibit late autophagy and dose-dependently increase lysosomal accumulation.
  • $148 TargetMol
In Stock
Size
QTY
USP28-IN-3
T747932931509-14-5In house
USP28-IN-3 is a highly selective USP28 inhibitor with an IC50 value of 0.1 μM against USP28.USP28-IN-3 exhibits anticancer activity and inhibits USP2, USP7, USP8, USP9x, UCHL3, and UCHL5.USP28-IN-3 is cytotoxic to human colorectal and lung squamous carcinoma cells, inhibiting c-cells and c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-neutralizing c-cells through the ubiquitin-proteasome system. -proteasome system to dose-dependently downregulate cellular levels of c-Myc.
  • $183 TargetMol
In Stock
Size
QTY
Astragaloside IV
T297384687-43-4
Astragaloside IV (AS-IV), an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1 2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. Astragaloside IV is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine.1 It dose-dependently inhibits human adenovirus type 3 (HAdV-3) in A549 cells (IC50 = 23 μM; LC50 = 865 μM).It inhibits replication of HAdV-3 and decreases HAdV-3-induced apoptosis. It has diverse protective effects for the cardiovascular, immune, digestive, and nervous systems. In particular, it reduces myocardial infarct size in dogs when administered prior to coronary ligation and reduces reperfusion arrhythmias in isolated rat hearts.
  • $32
In Stock
Size
QTY
TargetMol | Citations Cited
Propane-1,2,3-triyl tripalmitate
TWO2727555-44-2
Propane-1,2,3-triyl tripalmitate (Glycerol Tripalmitate) is a triacylglycerol found in dietary fats. In hamsters fed a diet enriched with it, Tripalmitin increases body weight, elevates plasma LDL levels, and reduces hepatic LDL receptor mRNA levels. It inhibits glucose-stimulated insulin secretion and decreases the viability of INS1 cells dose-dependently. Tripalmitin is used in cosmetic products for skin conditioning and as a thickening agent, and it forms lipid matrices of nanoparticles for drug delivery.
  • $30
In Stock
Size
QTY
[Sar9,Met(O2)11]-Substance P acetate
TP1369L
[Sar9,Met(O2)11]-Substance P acetate is a tachykinin NK1 receptor selective agonist. [Sar9,Met(O2)11]-Substance P acetate is a selective tachykinin NK1 receptor agonist.[Sar9,Met(O2)11]-Substance P acetate and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissimilar time-course. Both agonists increase dose-dependently face washing and sniffing while [Sar9,Met(O2)11]-Substance P acetate is the sole to produce grooming.
  • $92
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Y1 receptor antagonist 1
T12155221697-09-2In house
Y1 receptor antagonist 1 (H 409-22 isomer) is the active isomer of H-409/22, a neuropeptide Y (NPY) Y1 receptor antagonist that dose-dependently antagonizes the vascular response to exogenous and endogenous NPY in pigs. lagodeoxycholic acid (H 409-22 isomer) is the active isomer of H-409/22, an antagonist of neuropeptide Y (NPY) Y1 receptor.
  • $353
Backorder
Size
QTY
Galantide acetate
T15368L
Galantide acetate, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide acetate recognizes two classes of galanin binding sites (KD<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide acetate dose dependently (IC50=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide acetate appears to bind to a single population of SP receptors (KD~40 nM).
  • $158 TargetMol
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Tiflucarbine
T6816289875-86-5In house
Tiflucarbine is a potential non-selective 5-HT agonist with antidepressant activity.Tiflucarbine dose-dependently increased the specific activity of soluble calmodulin (CaM)-dependent phosphodiesterase in rat brain.
  • $280
In Stock
Size
QTY
Phe-Met-Arg-Phe, amide acetate
TP1858L
Phe-Met-Arg-Phe, amide acetate, activates a K+ current in peptidergic caudodorsal neurons dose-dependently (ED50=23 nM) and appears to localize with neuropeptide Y in some brain regions.
  • $46
In Stock
Size
QTY
TargetMol | Inhibitor Sale
H1k
T72057 In house
H1k is an eudistomin Y fluorescent derivative and lysosome-targeted antiproliferative agent that dose-dependently increases autophagy signalling and down-regulates the expression of cyclin-dependent kinase (CDK1) and cyclin B1.
  • $195
In Stock
Size
QTY
Litoxetine
T6795686811-09-8In house
Litoxetine is a selective 5-HT uptake inhibitor and is a 5-HT3 receptor antagonist. Litoxetine acts as an antidepressant and has shown antiemetic properties in ferrets. Litoxetine (1 and 10 mg kg i.v.) dose-dependently reduced the number of regurgitations and vomiting and delayed the onset of vomiting. Litoxetine has an affinity for brain 5HT3 receptors (Ki = 85 nM).
  • $98
In Stock
Size
QTY
USP28-IN-4
T747942931509-15-6
USP28-IN-4 is a potent USP28 inhibitor with an IC50 value of 0.04 μM against USP28. USP28-IN-4 exhibits anticancer activity and inhibits USP2, USP7, USP8, USP9x, UCHL3 and UCHL5. USP28-IN-4 is cytotoxic to human colorectal and lung squamous carcinoma cells and dose-dependently downregulates c-Myc cellular levels through the ubiquitin-proteasome system. -proteasome system to dose-dependently downregulate cellular levels of c-Myc.
  • $56
In Stock
Size
QTY
p-MPPF dihydrochloride
T69750223699-41-0In house
p-MPPF dihydrochloride is a selective 5-HT antagonist that dose-dependently antagonizes hypothermia induced by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and can be used to study neurological diseases.
  • $293
In Stock
Size
QTY
p-MPPF
T69750L155204-26-5In house
p-MPPF is a selective 5-HT antagonist that dose-dependently antagonizes hypothermia induced by 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and can be used to study neurological diseases.
  • $195
In Stock
Size
QTY
AMPK activator 4
T622382493239-46-4In house
AMPK activator 4 is a potent and selective AMPK activator that does not inhibit mitochondrial complex I. It selectively activates AMPK in muscle tissue, dose-dependently improves glucose tolerance in normal mice, significantly reduces fasting glucose levels, and improves insulin resistance in db db diabetic mice. [AMPK activator 4 has hypoglycemic effects.]
  • $83
In Stock
Size
QTY
MK-571 sodium
T3148115103-85-0
MK-571 sodium (L-660711 sodium salt) is a selective, orally active antagonist of the CysLT1 receptor. MK-571 sodium is a multidrug resistance protein-2 (ABCC2, Mrp2) inhibitor used to demonstrate the role of Mrp2 in the cellular efflux of drugs, xenobiotics, and their conjugates. MK-571 sodium can inhibit the synthesis of K-4′-O-GlcA (19.7 μM). MK571 dose-dependently inhibits the intracellular biosynthesis of all flavonol sulphates and glucuronides by Caco-2 cells. MK-571 sodium significantly inhibits phase-2 conjugation of kaempferol by cell-free extracts of Caco-2, and production of kaempferol-4′-O-glucuronide was competitively inhibited. In addition to inhibiting MRP2, MK571 is a potent inhibitor of enterocyte phase-2 conjugation.
  • $47
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Berberrubine chloride
T4S079515401-69-1
1. Berberrubine chloride (9-Berberoline Chloride) has antitumor activity. 2. Berberrubine has antidiabetic activity. 3. Berberrubine dose-dependently inhibits IL-8 and MCP-1 protein levels in the media and mRNA expression of the cells stimulated with IL-1beta or TNF-alpha.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
U-73343
TQ0159142878-12-4
U-73343 is an inactive analog of U-73122 and can be used as a negative control. It dose-dependently inhibits acid secretion irrespective of the stimulant. It is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50 of 1-2.1 μM for PLC.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
UNC926
T40121184136-10-4
UNC926 (UNC-926) inhibits L3MBTL1 (IC50: 3.9 μM). UNC926 also exhibits a low micromolar affinity for L3MBTL3. UNC926 inhibits binding of the 3xMBT domain to H4K20me1. It selectively and dose-dependently inhibits the L3MBTL13xMBT-H4K20me1 interaction. UNC926 has not an effect on the binding of 53BP1 to H4K20me1.
  • $29
In Stock
Size
QTY
TargetMol | Inhibitor Sale
ELOVL6-IN-1
T92141185736-98-4
ELOVL6-IN-1 is a potent, orally active, and selective ELOVL6 inhibitor that dose-dependently inhibits mouse ELOVL6 activities with an IC50 value of 0.350 μM. It inhibits ELOVL6 in a noncompetitive manner for malonyl-CoA (Ki=994 nM) and palmitoyl-CoA[1].
  • $70
In Stock
Size
QTY
TargetMol | Inhibitor Sale
3-​O-​Acetyloleanolic acid
T2S13964339-72-4
3-O-acetyloleanolic acid dose-dependently inhibited the viability of HCT-116 cells. Apoptosis was characterized by detection of cell surface annexin V and sub-G1 apoptotic cell populations.
  • $29
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Aumitin
T14346946293-78-3
Aumitin, a diaminopyrimidine-based autophagy inhibitor, dose-dependently inhibits starvation- and rapamycin-induced autophagy with IC50s of 0.12 μM and 0.24 μM, respectively [1], and also inhibits mitochondrial respiration by targeting complex I.
  • $59
In Stock
Size
QTY
TargetMol | Inhibitor Sale
GATA4-NKX2-5-IN-1
T11368544681-96-1
GATA4-NKX2-5-IN-1 exhibits no activity on the protein kinases involved in the regulation of GATA4 phosphorylation, and it modulates the hypertrophic agonist-induced cardiac gene expression.GATA4-NKX2-5-IN-1  dose-dependently inhibits the GATA4–NKX2-5 tran
  • $93
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BCL6-IN-6
T600082408882-54-0
BCL6-IN-6 is an inhibitor of Bcl-6 and can be used in studies about diffuse large B-cell lymphoma. BCL6-IN-6 blocks the interaction of Bcl-6 with its corepressors and dose-dependently reactivates Bcl-6 target genes.
  • $69
In Stock
Size
QTY
TargetMol | Inhibitor Sale
MCL0020
TP1889475498-26-1
MCL0020 is a potent and selective melanocortin MC4 receptor antagonist (IC50 values are 11.63, 1115, and >10,000 nM at MC4, MC3, and MC1 receptors, respectively). It significantly reverses stress-induced anorexia without affecting food intake in free-feeding rats and exhibits anxiolytic-like activity in vivo.
  • $118
In Stock
Size
QTY
TargetMol | Inhibitor Sale
XIAP/cIAP1 antagonist-1
T64302
XIAP cIAP1 antagonist-1 is a potent, orally active XIAP cIAP1 antagonist with an EC50 of 5.1 nM for XIAP and 0.32 nM for cIAP1, and dose-dependently inhibits tumor growth in vivo.
  • $1,520
10-14 weeks
Size
QTY
ZK110841
T29223105595-17-3
ZK110841 is an agonist of prostaglandin DP-receptors on human platelet. ZK110841 elevated the cyclic AMP level in EBTr cells dose-dependently, being more than 100 fold over the basal level at 1 microM.
  • $3,920
10-14 weeks
Size
QTY
NSC-658497
T24554909197-38-2
NSC-658497 is a SOS1-Ras interaction inhibitor that acts by dose-dependently inhibiting SOS1 GEF activity.
  • $1,520
6-8 weeks
Size
QTY
CU-2010
T716011021707-76-5
CU-2010 is a synthetic serine protease inhibitor with antifibrinolytic and anticoagulant properties. CU-2010 dose-dependently reduces postoperative blood loss and improves postischemic recovery after cardiac surgery in a canine model.
  • $2,570
10-14 weeks
Size
QTY
(±)18-HETE
T35467133268-58-3
(±)18-HETE is the racemic version of a cytochrome P450 (CYP450) metabolite of arachidonic acid. When formed by the CYP2E1 isoform, 18-HETE is comprised 100% of the (R) isomer. 18(R)-HETE dose-dependently stimulates vasodilation of the rabbit kidney, whereas 18(S)-HETE does not affect perfusion pressure. 18-HETE has negligible effects on ATPase activity. 18(R)-HETE at 1 μM completely blocks 20-HETE-induced vasoconstriction of renal arterioles.
  • $365
35 days
Size
QTY
Malformin C
T3696159926-78-2
Malformin C is a natural fungus-derived bicyclic pentapeptide that has antibacterial properties, particularly against species of Bacillus. Malformin C potently blocks the ability of bleomycin to induce G2 arrest in human T-cell leukemia-derived Jurkat cells (IC50 = 0.9 nM). It less potently abrogates colchicine-induced M phase arrest in Jurkat cells (IC50 = 24 nM). Malformin C inhibits cell growth dose-dependently in Colon 38 and HCT 115 cancer cells (IC50s = 0.27 and 0.18 μM, respectively) but has a low therapeutic index against cancer xenografts when tested in mice.
  • $568
35 days
Size
QTY
PXS-5153A monohydrochloride
T12585L
PXS-5153A monohydrochloride is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic (LOXL2/LOXL3) inhibitor, with an IC 50 of <40 nM for LOXL2 across all mammalian species and an IC 50 of 63 nM for human LOXL3. PXS-5153A monohydrochloride dose-dependently reduced LOXL2-mediated collagen oxidation and collagen crosslinking in vitro which may represent an innovative therapeutic approach for the treatment of fibrosis
  • $987
10-14 weeks
Size
QTY
DW532
T710821267949-42-7
DW532 is one of simplified analogues of hematoxylin that has shown broad-spectrum inhibition on tyrosine kinases and in vitro anti-cancer activities. DW532 inhibited EGFR and VEGFR2 in vitro kinase activity (the IC50 values were 4.9 and 5.5 μmol/L, respectively), and suppressed their downstream signaling. DW532 dose-dependently inhibited tubulin polymerization via direct binding to tubulin, thus disrupting the mitotic spindle assembly and leading to abnormal cell division. In a panel of human cancer cells, DW532 (1 and 10 μmol/L) induced G2/M phase arrest and cell apoptosis, which subsequently resulted in cytotoxicity. Knockdown of BubR1 or Mps1, the two core proteins of the spindle assembly checkpoint dramatically decreased DW532-induced cell cycle arrest in MDA-MB-468 cells. Moreover, treatment with DW532 potently and dose-dependently suppressed angiogenesis in vitro and in vivo. ( Acta Pharmacol Sin. 2014 Jul;35(7):916-28.)
  • $1,520
6-8 weeks
Size
QTY
AM-211 sodium
T710881263077-74-2
AM-211 sodium is a novel and potent antagonist of the prostaglandin D2 receptor type 2. AM-211 is active in animal models of allergic inflammation. AM211 has high affinity for human, mouse, rat, and guinea pig DP2 and it shows selectivity over other prostanoid receptors and enzymes. AM211 exhibits good oral bioavailability in rats and dogs and dose-dependently inhibits 13,14-dihydro-15-keto-PGD(2)-induced leukocytosis in a guinea pig pharmacodynamic assay.
  • $1,520
6-8 weeks
Size
QTY
AZD1283
T3536919351-41-0
AZD1283 is an effective P2Y12 receptor antagonist (EC50: 3.0 ug kg min, binding IC50: 11 nM). AZD1283 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg kg min, respectively. The doses induced the increase in bleeding time at 33 and 100 μg kg min for 3- and 13-fold, respectively. Thus, the therapeutic index (TI) was ≥10 for both compounds.
  • $31
In Stock
Size
QTY
AT-1001
T709871314801-63-2
AT-1001 is an α3β4 nAChR partial agonist. AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats. AT-1001 also potently and reversibly blocks epibatidine-induced inward currents in HEK cells transfected with α3β4 nAChR. Importantly, AT-1001 potently and dose-dependently blocks nicotine self-administration in rats, without affecting food responding. When tested in a nucleus accumbens (NAcs) synaptosomal preparation, AT-1001 inhibits nicotine-induced [³H]dopamine release poorly and at significantly higher concentrations compared with mecamylamine and conotoxin MII.
  • $1,520
6-8 weeks
Size
QTY
CAY10669
T358181243583-88-1
CAY10669 is an inhibitor of the histone acetyltransferase PCAF (p300/CREB-binding protein-associated factor; IC50 = 662 μM), displaying a 2-fold improvement in inhibitory potency over anacardic acid . At 30-60 μM, CAY10669 can dose-dependently inhibit histone H4 acetylation in HepG2 cells in vitro.
  • $198
35 days
Size
QTY
JC-171
T381062112809-98-8
JC-171, a selective inhibitor of the NLRP3 inflammasome, effectively inhibits LPS ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages with an IC50 of 8.45 μM[1].
  • $297
7-10 days
Size
QTY
WO-459
T709931313195-84-4
WO-459 is a novel GPR52 agonist, dose-dependently inducing elevation of intracellular cAMP in HEK293/GPR52 cells.
  • $1,670
6-8 weeks
Size
QTY
AEZS-112
T712181214741-69-1
AEZS-112, also known as ZEN012, is an orally active small mol. anti-cancer drug which inhibits the polymn. of tubulin at low micromolar concns. AEZS 112 dose-dependently increased non-vital hypodiploid cells and the cytotoxic effect was least pronounced in G2 phase of the cell cycle, indicating cell death during mitosis, as detd. by FACS anal. AEZS 112 showed anti-tumor activity in human ovarian and endometrial cancer cell lines at low micromolar concns., which could not be abrogated by caspase inhibition and is therefore a good candidate for in vivo studies in these tumors.
  • $1,520
6-8 weeks
Size
QTY
CCG-63808
T14898620113-73-7
CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins, dose-dependently inhibiting the TR-FRET signal between RGS4-AF488 and Tb-Gαo with an IC50 value of 1.9 μM.
  • $43
In Stock
Size
QTY
RWJ-56110 dihydrochloride
T367172387505-58-8
RWJ-56110 dihydrochloride is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 μM), showing no effect on PAR-2, PAR-3, or PAR-4. It inhibits the aggregation of human platelets induced by SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM), with high selectivity relative to U46619. RWJ-56110 dihydrochloride also blocks angiogenesis and the formation of new vessels in vivo, and induces cell apoptosis[1][2].
  • $481
Backorder
Size
QTY
Dyrk1A-IN-5
T617391685235-41-9
Dyrk1A-IN-5 (compound 5j) is a highly potent and selective DYRK1A inhibitor with an IC50 of 6 nM, reducing the phosphorylation of Thr434 in SF3B1 dose-dependently (IC50 = 0.5 μM) and inhibiting tau phosphorylation at Thr212 (IC50 = 2.1 μM), making it valuable for Down syndrome research [1].
  • $1,070
6-8 weeks
Size
QTY
AX 048
T37182873079-69-7
The group IVA phospholipase A2 (PLA2), known as calcium-dependent cytosolic PLA2 (cPLA2), selectively releases arachidonic acid from membrane phospholipids, playing a central role in initiating the synthesis of prostaglandins and leukotrienes. AX 048 is a potent group IVA cPLA2 inhibitor that demonstrates 50% inhibition of the enzyme at a mole fraction (XI(50)) of 0.022. Pretreatment with AX 048 (ED50 = 1.2 mg/kg) dose-dependently reduces thermal hyperalgesia evoked by carrageenan injection of rat hind paw. At concentrations as high as 30 μM, AX 048 does not inhibit COX activity or interfere with central cannabinoid receptor signaling.
  • $373
35 days
Size
QTY
Phe-Met-Arg-Phe, amide
TP185864190-70-1
Phe-Met-Arg-Phe, amide dose-dependently (ED50=23 nM) activates a K+ current in peptidergic caudodorsal neurons and appears to localize with neuropeptide Y in some brain regions.
  • $76
Backorder
Size
QTY
Lucidumol A
TN6645217476-73-8
Lucidumol A has relatively good effect against aldose reductase with IC50 of 19.1uM. Lucidumol A has cytotoxic activity, it reduced cell growth in three human carcinoma cells (Caco-2, HepG2, and HeLa cells) dose dependently with LC50s from 20.87 to 84.36
  • $900
Backorder
Size
QTY
PACAP (1-38), human, ovine, rat TFA
TP1054
PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP),
  • $130
Backorder
Size
QTY